Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Accepts WTO Amendment to Enhance Access to Drugs (China)

This article was originally published in PharmAsia News

Executive Summary

The Standing Committee of the National People's Congress, China's top legislature, has accepted an amendment to the WTO Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) to improve access to medicines when dealing with public health emergencies. The amendment allows countries to override patent rights when necessary to export life-saving pharmaceuticals to developing countries that are facing public health crises but cannot produce drugs for themselves. The amendment also makes permanent the flexibility of developing and least developed members to produce or import generic copies of patented drugs to deal with epidemics. "The amendment will play a positive role in balancing relations between intellectual property rights protection and public health promotion, helping developing and least developed countries to deal with public health problems as well," said Ma Xiuhong, Vice Minister of Commerce. The amendment will be formally incorporated into the TRIPS Agreement when two thirds of the WTO members have ratified it. Members have until Dec. 1, 2007 to do so. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel